News

Optimization of Enoxaparin Dosing in Obese Patients

4. 4. 2022 Source: Thromboprophylaxis

Obesity is a risk factor for venous thromboembolism; however, there is uncertainty regarding the optimal dose of enoxaparin for treating acute episodes in the obese population. Two observational studies published last year focused on the efficacy and safety of enoxaparin depending on the dose. The standard dose of 1 mg/kg may be too high for some patients, and fixed dosing without monitoring Xa levels may not be adequate.

Enoxaparin in the Treatment of Pulmonary Embolism in a Morbidly Obese Patient –⁠ Case Report

The number of patients suffering from overweight and obesity has been steadily increasing in recent years. Obesity is one of the independent risk factors for thromboembolic disease. Treating…

4. 4. 2022 Source: Thromboprophylaxis

Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma –⁠ A Case Study

We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with numerous comorbidities and complications due to long-term systemic corticosteroid therapy. Significant…

4. 4. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

hospitalizovaná pacienta covid nemocnice péče

Comparison of Enoxaparin and Unfractionated Heparin in Hospitalized Patients in Terms of Clinical and Cost Effectiveness

Thromboembolic disease represents one of the severe complications in hospitalized patients. Low molecular weight and unfractionated heparin are most commonly used during hospitalization as part of…

31. 3. 2022 Source: Thromboprophylaxis

Efficacy of L. reuteri DSM 17938 in the Treatment of Infantile Colic

Infantile colic represents a syndrome of behavioral disorders in infants characterized by episodes of uncontrollable crying, wailing, and restlessness without an identifiable cause. This is a common…

30. 3. 2022 Source: GI, colic and microbiome

Continuation of Treatment with Tofacitinib in Rheumatoid Arthritis –⁠ Real-World Clinical Practice Data

The oral Janus kinase inhibitor tofacitinib has been extensively tested in patients with rheumatoid arthritis in numerous international randomized clinical trials. According to a recently published…

29. 3. 2022 Source: Arthritis

COVID-19 in Patients with Acquired Hemophilia A −⁠ Case Reports

At the XXVIII. Pařízek Days held in Ostrava, on the afternoon of March 17, 2022, Dr. Anna Maria Pejková from the 4th Internal Clinic of the University Hospital Hradec Králové presented 3 case reports…

29. 3. 2022 Source: Acquired Hemophilia

Is it beneficial to combine etanercept and methotrexate in the treatment of psoriatic arthritis?

The study presented below by Canadian, American, and British authors focused on comparing the efficacy of monotherapy with methotrexate, etanercept, and their combination in patients with psoriatic…

28. 3. 2022 Source: Arthritis

Participation in sports activities, frequency and severity of sports injuries in children with hemophilia

Children with hemophilia used to be discouraged from engaging in sports activities due to the potential increased risk of bleeding. The introduction of prophylaxis into routine practice has improved…

28. 3. 2022 Source: Hemophilia with Movement

Získaná hemofilie A nově diagnostikovaná u pacientky v pokročilém věku − kazuistika

Acquired Hemophilia A Newly Diagnosed in an Elderly Patient −⁠ A Case Report

At the XXVIIIth Pařízek Days held in Ostrava, a case of acquired hemophilia A, recently addressed at this institution, was presented in the afternoon session on March 17, 2022, by Assoc. Prof. Petr…

28. 3. 2022 Source: Acquired Hemophilia

PHD 2022: In the treatment of multiple myeloma we have achieved significant progress, confirm real-world data

The treatment options for multiple myeloma (MM) have significantly advanced over the past 10 years, and patient outcomes have improved. However, the most accurate guide is needed to select the right…

28. 3. 2022 Source: Hematologic Malignancies

Hodgkin Lymphoma in a Summary of News from Post-ASH 2021

Dr. Anna Suredová from the Clinical Hematology Department of the Catalonian Oncology Institute in Barcelona, newly elected president of the European Society for Bone Marrow Transplantation (EBMT),…

28. 3. 2022 Source: Hematologic Malignancies

Current Insights into the Etiology of Community Pneumonia: Pneumococci Still Leading?

The etiology of community-acquired pneumonias has undergone certain changes since the beginning of the antibiotic era. According to current guidelines, it is still recommended to initiate empirical…

25. 3. 2022 Source: Anti-Infectives

Safe Long-term Treatment of Nasal Symptoms in Patients with Perennial Allergic Rhinitis

In persistent allergic rhinitis, achieving symptom control is often difficult despite pharmacological treatment and minimizing contact with the allergen. Good efficacy in clinical studies has been…

24. 3. 2022 Source: Life Without Allergic Rhinitis

Effect of Combination Therapy on Symptoms of Allergic Rhinitis

The aim of the study presented below by authors from the USA was to evaluate the efficacy, safety, and tolerability of treatment with the nasal spray GSP301 containing a fixed combination of active…

24. 3. 2022 Source: Life Without Allergic Rhinitis

1 … 57 58 59 60 61 … 115

Back Filter by speciality

Remove filters